Innate Pharma (IPHA) Research & Development (2019 - 2024)
Historic Research & Development for Innate Pharma (IPHA) over the last 6 years, with Q4 2024 value amounting to -$55.5 million.
- Innate Pharma's Research & Development rose 784.84% to -$55.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$169.6 million, marking a year-over-year increase of 214.62%. This contributed to the annual value of $56.3 million for FY2024, which is 716.18% down from last year.
- As of Q4 2024, Innate Pharma's Research & Development stood at -$55.5 million, which was up 784.84% from -$60.3 million recorded in Q4 2023.
- Over the past 5 years, Innate Pharma's Research & Development peaked at -$52709.0 during Q4 2022, and registered a low of -$60.3 million during Q4 2023.
- Its 5-year average for Research & Development is -$45.8 million, with a median of -$55.5 million in 2024.
- As far as peak fluctuations go, Innate Pharma's Research & Development skyrocketed by 9990.2% in 2022, and later crashed by 11425668.68% in 2023.
- Quarter analysis of 5 years shows Innate Pharma's Research & Development stood at -$59.3 million in 2020, then rose by 9.27% to -$53.8 million in 2021, then skyrocketed by 99.9% to -$52709.0 in 2022, then crashed by 114256.69% to -$60.3 million in 2023, then rose by 7.85% to -$55.5 million in 2024.
- Its Research & Development was -$55.5 million in Q4 2024, compared to -$60.3 million in Q4 2023 and -$52709.0 in Q4 2022.